In a reversal, the FDA is reconsidering its decision to end the shortage status of tirzepatide, after a recent lawsuit and intense public pressure, The Washington Post reported Oct. 21.
For once, the U.K.’s health technology assessment body, the National Institute of Health and Care Excellence (NICE), has no reservations about the cost effectiveness of a new drug and is recommending ...
The reconsideration follows an Oct. 11 lawsuit that prompted U.S. District Judge Mark Pittman to temporarily halt legal proceedings to give the FDA time to reassess its ruling.